Slide 1: Building a Leading Franchise: Next Generation FcRn IMVT-1402
\f IMMUNOVANT Building a Leading Franchise + Next Generation FcRn: IMVT- al + us A September 2022 _
Slide 2: Forward-looking statements
Forward-looking statements tse of words such a8 ean "may. "might” wi” "woud “sul” expat” "al la ‘atts ‘sty or Fick Facore croteenee, ‘mar ness these ete. ff immunovanr,
Slide 3: Our vision: Normal lives for people with autoimmune disease
Our vision: Normal lives for people with autoimmune disease Driven by our core values Love Bolder, All Trailblazing Faster Voices ff immunovan
Slide 4: Building a leading anti-FcRn franchise: Introducing IMVT-1402
Building a leading anti-FcRn franchise: Introducing IMVT-1402 IMVT-1402 + + + ‘Novel, fully human, monoclonal antibody inhibiting FcRn- of IgG IMVT-1402 is culmination of i Animal studies' have demonstrated IMVT-1402 may have deep, potentially best-in-class IgG lowering, similar to batoclimab, and y
Slide 5: FcRn inhibition has broad potential
FcRn inhibition has broad potential autoimmune diseases: 19 announced indications’ across multiple therapeutic areas create clinical and commercial? opportunity for a franchise approach ff immunovan NEUROLOGY Myasthenia gravis (MG) HEMATOLOGY polyneuropathy (CIDP) Myositis Autoimmune encephalitis My
Slide 6: Anti-FcRn market is unique in terms of breadth of potential
Anti-FcRn market is unique in terms of breadth of potential indications and in terms of having a strong biomarker [ > 196 reduction is a well-established biomarker for degree of clinical response! | YY) S2me Patient populations and indications likely need maximal IgG suppression (up to ~80%) to maxi
Slide 7: Next-generation anti-FcRn: IMVT-1402
+ Next-generation anti-FcRn: IMVT-1402 tet et ff immunovant
Slide 8: IMVT-1402 has potentially best-in-class attributes to address large unmet need
IMVT-1402 has potentially best-in-class attributes to address large unmet need in autoimmune disease oO DEEP IgG LOWERING je ] CONVENIENT ADMINISTRATION Ib LOL. Se FAVORABLE ANALYTE PROFILE : 5 rocont COMPELLING PATENT PROTECTION? Pending 1402 composition of matter patent expiring 2042+ sein mempeon
Slide 9: IMVT-1402 and batoclimab demonstrate similar IgG reduction
IMVT-1402 and batoclimab demor reduction Head-to-Head Monkey Study 1G concentration (mg/mL), mean porcont change from baseline + SD 100 d similar, 1 Dose administration 20 monkeys, dosed IV in head-to-head study ‘across four groups ‘At comparable doses, IgG lowering is similar for both batoclimab an
Slide 10: IMVT-1402 and placebo demonstrate similar albumin and LDL
IMVT-1402 and placebo demor 1 similar alk in and LDL Head-to-Head Monkey Study ), mean * SD ),meantSD LDL ), mean £: 7 7 af 2 a ola it ° pa Day Day Day — Batocimab 50 mg/kg (n=3) — IMVT-1402 50 mgikg (0=7) — IMVT-1402 5 malig (n=7) — Placebo (n=3) {ff immunovant £2 state Ngo trons outa nn en, Fmt on
Slide 11: IMVT-1402 is designed to deliver maximum IgG reduction
IMVT-1402 is designed to deliver maximum IgG reduction while minimizing interference with the albumin binding site
Slide 12: IMVT-1402 development is well underway, with initial Phase 1 data expected in mid-2023
IMVT-1402 development is well underway, with initial Phase 1 data expected in mid-2023 ‘Ongoing in-house development IMVT-1402 if Novel, fuly human, rmonocional antbody inhibiting FeRn-mediated recyoing of 196 GMP drug product manufacture completed sh runway guidance into 202512 Forint Astonces ny 1
Slide 13: ff immunovant
ff immunovant tet et
Slide 14: Building an anti-FcRn franchise with differentiated assets to address a range of patient needs
Building an anti-FcRn franchise with differentiated assets to address a range of patient needs Batoclimab + 5 & £y 4 IMVT-1402 A a & a 4 ff immunovan ; “4 Tailored dosing to address varying symptom severity across indications and stage of disease + Short term maximal IgG suppression + Lower chronic
Slide 15: Building an anti-FcRn franchise with a rational development strategy
Building an anti-FcRn franchise with differentiated assets and a rational development strategy to optimize ability to address unmet need Batoclimab IMVT-1402 + a cb + © + a + a + < + Induction and Maintenance in MG, CIDP Sustained, maximal IgG suppression in Fixed Duration in TED additional therapeu
Slide 16: Planning to leverage batoclimab learnings to accelerate development of IMVT-1402
Planning to leverage data and learnings from batoclimab to accelerate development of IMVT-1402 Potential case study in Graves’ Disease Batoclimab Phase 2 fi imvT-1402 dosing to be |f) Combine leaming to informed by parallel initiate planned pivotal planned Phase 1 trial trial with IMVT-1402 ff immun
Slide 17: Batoclimab and IMVT-1402 have the potential to offer multiple differentiated product features
Batoclimab and IMVT-1402 have the potential to offer multiple differentiated product features, if approved Immunovant Franchise Product and program attributes efgartigimod' _batoclimab _| iiviea40z2 IgG reduction ~65% x x x IgG reduction ~80% x x ‘Aloumin/LDL changes: none or minimal x x ‘Subcutaneo
Slide 18: Franchise value is maximized by developing both batoclimab and IMVT-1402
We believe franchise value is maximized by developing both batoclimab and IMVT-1402 ff immunovan Lead asset batoclimab full speed ahead in pivotal programs for MG, TED and CIDP Earlier batoclimab launches may provide faster path to positive cash flow and enable commercial’ synergies across the franc
Slide 19: ff immunovant
ff immunovant tee et +h ett ++ ++ tee
Slide 20: Multiple paths to enhanced value creation when batoclimab and IMVT-1402 are developed together
Multiple paths to enhanced value creation when batoclimab and IMVT-1402 are developed together We believe franchise value is maximized in both the near and longer term‘ GD: Phase2 Thal ) [GD: inal Resuts at TED: Topine Route Tal tition = tiation | eee Ameren all wats » 202: —— —_ 2025 2026 TED: nati
Slide 21: A leader in FcRn inhibitor technology dedicated to enabling normal lives
A leader in FcRn inhibitor technology dedicated to enabling normal lives for people with autoimmune diseases Batoclimab full speed ahead in MG, TED and CIDP IMVT-1402 designed for differentiation across the key product features for anti-FcRns ‘+ Multiple paths to enhanced value creation when batocli